On January 15, 2026, ImmunityBio experienced a remarkable surge in its stock price, closing at $3.95, marking a substantial increase of 30.80% for the trading session. This significant jump was driven by the company’s impressive preliminary results for 2025, which revealed a staggering 700% growth in revenue from its bladder cancer therapy, Anktiva. The company’s quarterly sales figures surpassed expectations, leading to heightened investor interest and trading activity.
Trading volume soared to 74 million shares, dramatically surpassing the three-month average of 12 million shares by approximately 442%. The strong performance of ImmunityBio stood in contrast to its historical performance since its initial public offering in 2015, during which the stock has plummeted 89%.
The broader market also saw modest gains, with the S&P 500 rising 0.27% to close at 6,945, while the Nasdaq Composite increased by 0.25% to finish at 23,530. Within the biotechnology sector, peers such as Incyte and Vertex Pharmaceuticals lagged behind ImmunityBio, closing at $105.24 and $438.92, respectively, both reflecting minor declines.
For investors, the developments at ImmunityBio signal a promising turnaround. The preliminary full-year earnings report suggests that sales from Anktiva could grow from $15 million in 2024 to an impressive $113 million in 2025, indicating a quarter-over-quarter increase of 20%. This surge in revenue aligns with the recent approval of Anktiva by the Saudi Food and Drug Authority, which further fueled the stock’s upward momentum.
Additionally, positive data announced a few days prior regarding Anktiva’s efficacy for non-small cell lung cancer hints at further expansion opportunities for the therapy. These developments position ImmunityBio as a noteworthy player in the healthcare sector, particularly given its potential to enter new geographic markets and indications. However, investors are cautioned that the stock may experience volatility moving forward.
